Marker Therapeutics reports evidence from Phase 1 APOLLO study

Marker Therapeutics (MRKR) reported scientific evidence from the Phase 1 APOLLO study demonstrating that lymphodepletion improves the expansion and persistence of MAR-T cells. The Company’s Phase 1 APOLLO study is investigating MT-601, a MAR-T cell product, in patients with lymphoma who have relapsed after anti-CD19 chimeric antigen receptor-T cell therapy or for whom anti-CD19 CAR-T cell therapy is not an option. In December, the Company provided an update on the progress and clinical observations from the study, with a data cutoff date of September 10, 2024. This update included clinical data from 9 patients from 5 clinical sites in the United States. Infusion of MT-601 was well tolerated in all study participants with no dose limiting toxicities, including immune-effector cell associated neurotoxicity syndrome. Objective responses were achieved in 7 out of 9 patients, with 4 patients demonstrating complete response as early as 4 weeks after infusion of MT-601.